Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack drug combo may unclog arteries when standard methods fail

NCT ID NCT04573751

Disease control Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial tested whether giving epinephrine and verapamil directly into the heart arteries could help restore blood flow in heart attack patients whose vessels remain blocked despite standard treatment. 104 adults with ST-elevation heart attacks were enrolled. The study compared standard therapy alone versus adding epinephrine, verapamil, or both.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
epinephrine and verapamil (given directly into the heart arteries)
What this could lead to
If it works, this could give doctors a new way to restore blood flow during a heart attack when standard treatments fail.
What could go wrong
This is a small, completed trial with 104 participants, so results may not apply to all patients. The drugs can affect blood pressure and heart rhythm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

104 people

The number who actually took part.

Started

Dec 2020

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with ST-elevation myocardial infarction * Infarct-related artery TIMI flow grade 0-2 during the interventional procedure after the initial opening of the vessel. * Written the informed consent to participate in research Exclusion Criteria: * Unable to undergo or contra-indications for MRI or SPECT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for No-reflow phenomenon are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

No-Reflow Phenomenon ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

No-reflow phenomenon Percutaneous coronary intervention ST elevation myocardial infarction

Contacts and locations

Locations

  • Cardiology Research Institute, Tomsk NRMC

    Tomsk, Tomsk Oblast, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.